Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

United Therapeutics Reports ‘Solid’ Fourth Quarter As Inhaled Remodulin Gains Fans

This article was originally published in The Pink Sheet Daily

Executive Summary

Look for NDA filing for Viveta in June, approval in first half of 2009, analyst tells “The Pink Sheet” DAILY.

You may also be interested in...



United Therapeutics Replaces Oral Treprostinil With Lilly’s Tadalafil In PAH – For Now

Non-shocking Phase III blowup coincides with U.S. deal for rights to drug already cleared for erectile dysfunction.

United Therapeutics Replaces Oral Treprostinil With Lilly’s Tadalafil In PAH – For Now

Non-shocking Phase III blowup coincides with U.S. deal for rights to drug already cleared for erectile dysfunction.

United Therapeutics’ Inhaled Treprostinil May Get Second Quarter 2009 Action Date

NDA for the new formulation of Remodulin for pulmonary arterial hypertension was filed June 27.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS067268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel